Promising combo for tough prostate cancer falls short in early trial
NCT ID NCT03360721
First seen Feb 11, 2026 · Last updated May 17, 2026 · Updated 11 times
Summary
This study tested a combination of two drugs, apalutamide and abiraterone acetate, plus prednisone, in men with castration-resistant prostate cancer that had spread. The goal was to see if the combo could slow cancer growth. Only 7 people enrolled before the study was stopped early, so results are limited. Participants had to continue hormone therapy and take prednisone to manage side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.